Lilly's 'triple-G' obesity drug reaches bariatric-surgery-level weight loss in trial
Eli Lilly has published Phase 3 trial results for retatrutide (development name LY3437943), the candidate it is positioning as a next-generation obesity drug, in the New England Journal of Medicine. The 72-week double-blind study recorded an average 24% weight loss in patients on treatment — markedly higher than current GLP-1 class drugs.
The 'triple-G' nickname comes from the fact that retatrutide targets not only the GLP-1 (glucagon-like peptide-1) receptor but also GIP and glucagon receptors. The triple-receptor mechanism produces both appetite suppression and thermogenesis (the body's heat-generating energy expenditure). Lead author Dr Ania Jastreboff of Yale University said, 'This combination of mechanisms delivers weight loss above what GLP-1 monotherapies can achieve alone — and the loss falls in a range similar to bariatric surgery outcomes.'
The study enrolled 2,300 adult participants aged 18 and over, with a mean starting body mass index (BMI) of 37.4. Patients were tracked in four dose groups: 1 mg, 4 mg, 8 mg and 12 mg, all administered as weekly injections. At the highest dose, 72-week mean weight loss reached 24%, against 2.1% in the placebo group. The 8 mg arm delivered 21% loss and 4 mg 17%.
The side-effect profile, however, was prominent in the disclosure. At the 12 mg dose, 16% of patients discontinued — primarily because of gastrointestinal adverse events (nausea, vomiting, diarrhoea). That is above the 5-7% discontinuation rate typical of existing GLP-1 drugs. Lilly's chief medical officer Dr Daniel Skovronsky said at a press call that 'this is manageable through the dose-titration protocol,' and that the recommended clinical practice will involve a 6-8 week up-titration schedule.
Cost and access questions emerged quickly. Lilly has not yet released a price, but analysts expect a list price in the $1,000-$1,500 a month range — similar to other GLP-1 drugs. The Maryland Health Services Cost Review Commission's decision earlier this year to place a price cap on Ozempic has triggered similar state-level activity across the United States; retatrutide is expected to face comparable pressure on launch.
One of retatrutide's most striking features is its cardiovascular effect. The trial recorded an average 8 mmHg drop in systolic blood pressure, a 1.9-point improvement in HbA1c, and a 19% reduction in LDL cholesterol. Whether these metabolic improvements translate to long-term reductions in heart-attack and stroke risk is the scope of the five-year SUMMIT-CV outcomes trial Lilly plans to launch.
The GLP-1 drug class has been the fastest-growing area of global pharmaceuticals over the past three years. Novo Nordisk's Wegovy and Ozempic, together with Lilly's Mounjaro and Zepbound, reached combined annual sales of about $90 billion in 2025. Retatrutide, with both its weight-loss magnitude and possible cardiovascular benefit, could deepen Lilly's leadership in this market.
Other manufacturers' responses are also notable. Novo Nordisk's CagriSema (cagrilintide + semaglutide), in development, showed a 22% weight loss at 68 weeks; Pfizer's oral danuglipron failed to advance to Phase 3 because of discontinuation rates. Boehringer Ingelheim's survodutide, developed jointly with Zealand Pharma, uses a similar triple mechanism and is expected to read Phase 3 data later this year.
Lilly is expected to file with the US Food and Drug Administration (FDA) for retatrutide approval by year's end. Market entry is likely in the third quarter of 2026. For patients weighing the implications, medical guidance is essential; obesity treatment is a complex medical area, drugs may be one option, but a holistic approach — lifestyle, nutrition and, where appropriate, surgical options — matters.
Disclaimer: This article is for information only and is not a substitute for medical advice. Any treatment decision regarding obesity or weight management should be discussed with a doctor who is reviewing your clinical history, current medications and overall health.